Animal models of diabetic neuropathic pain

Neuromethods

Volumn 49, Issue , 2011, Pages 147-169

  Dobretsov, Maxim ^a   Backonja, Miroslav Misha ^b   Romanovsky, Dmitry ^a   Stimers, Joseph R ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE; VANILLOID RECEPTOR 1;

ALLODYNIA; BEHAVIOR CHANGE; CHRONIC PAIN; DIABETIC NEUROPATHY; DISEASE MODEL; HEAT SENSITIVITY; HUMAN; HYPERALGESIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MYALGIA; NERVE DEGENERATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; REVIEW; STREPTOZOCIN DIABETES; VOCALIZATION; WITHDRAWAL REFLEX;

ANIMALIA; RODENTIA;

EID: 77957915738     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/978-1-60761-880-5_9     Document Type: Review

References (167)

1. American Diabetes Association. Diagnosis and classifcation of diabetes mellitus. Diabetes Care 2008; 31(1 Suppl):S55-S78.
2. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27:1458-1483
3. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda MD: NIH Publication, 1995: 95-1468.
4. Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M et al. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007; 23(9):2035-2042.
5. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabe-tes. Diabetes Care 2006; 29(7):1518-1522.
6. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006; 20(1):26-33.
7. Boulton AJ. Management of diabetic periph-eral neuropathy Clin Diabetes 2005; 23:9-15.
8. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med 2006; 23(9):1021-1024.
9. Belgrade MJ, Cole BE, McCarberg BH, McLean MJ. Diabetic peripheral neuropathic pain: case studies. Mayo Clin Proc 2006; 81(4 Suppl):S26-S32.
10. Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE et al. Consensus guidelines: treatment planning and options. Mayo Clin Proc 2006; 81(4 Suppl):S12-S25.
11. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21(9):976-982.
12. Woolf CJ, Mannion RJ. Neuropathic pain: aeti-ology, symptoms, mechanisms, and manage-ment. Lancet 1999; 353(9168):1959-1964.
13. Calcutt NA, Backonja MM. Pathogenesis of pain in peripheral diabetic neuropathy. Curr Diab Rep 2007; 7(6):429-434.
14. Sindrup SH, Jensen TS. Effcacy of pharma-cological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83(3):389-400.
15. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with impaired glucose tolerance: implications for diagnosis and therapy. Curr Treat Options Neurol 2005; 7(1):33-42.
16. Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983; 46(6):491-499.
17. Benn SC, Costigan M, Tate S, Fitzgerald M, Woolf CJ. Developmental expression of the TTX-resistant voltage-gated sodium chan-nels Nav1.8 (SNS) and Nav1.9 (SNS2) in primary sensory neurons. J Neurosci 2001; 21:6077-6085.
18. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2002; 57(1):45-51.
19. Shun CT, Chang YC, Wu HP, Hsieh SC, Lin WM, Lin YH et al. Skin denervation in type 2 diabetes: correlations with diabetic dura-tion and functional impairments. Brain 2004; 127(Pt 7):1593-1605.
20. Sorensen L, Molyneaux L, Yue DK. The level of small nerve fber dysfunction does not predict pain in diabetic neuropathy: a study using quantitative sensory testing. Clin J Pain 2006; 22(3):261-265.
21. Sorensen L, Molyneaux L, Yue DK. The rela-tionship among pain, sensory loss, and small nerve fbers in diabetes. Diabetes Care 2006; 29(4):883-887.
22. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fbre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1994; 11(1):17-21.
23. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneu-ropathy. Correlations with clinical features and subsequent changes in neurophysiol-ogy. Diabetes Care 1988; 11(1):34-40.
24. Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF. Variable relation-ship between peripheral somatic and auto-nomic neuropathy in patients with different syndromes of diabetic polyneuropathy Diabetes 1986; 35(2):192-197.
25. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43(4):817-824. (Pubitemid 23121981)
26. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropa-thy. Diabetes Care 1993; 16:1103-1115.
27. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000; 23(4):510-517.
28. Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH. Pain phenomena and possible mecha-nisms in patients with painful polyneuropa-thy. Pain 2003; 101(1-2):187-192.
29. Proceedings of a consensus development con-ference on standardized measures in diabetic neuropathy Clinical measures. Neurology 1992; 42:1823-1825.
30. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy Neurologist 2008; 14:23-29.
31. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 787-798.
32. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005; 22(4):359-370.
33. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29(3):643-649.
34. Romanovsky D, Cruz NF, Dienel GA, Dobretsov M. Mechanical hyperalgesia correlates with insulin defciency in normoglyce-mic streptozotocin-treated rats. Neurobiol Dis 2006; 24:384-394.
35. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 1969; 48(11):2129-2139.
36. Wang LX, Wang ZJ. Animal and cellular models of chronic pain. Adv Drug Deliv Rev 2003; 55(8):949-965.
37. Eaton M. Common animal models for spasticity and pain. J Rehabil Res Dev 2003; 40(4 Suppl 1):41-54.
38. Rice AS, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I et al. Animal models and the prediction of effcacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform report-ing standards. Pain 2008; 139(2):243-247.
39. Vissers K, De Jongh R, Hoffmann V, Heylen R, Crul B, Meert T. Internal and external factors affecting the development of neuro-pathic pain in rodents. Is it all about pain? Pain Pract 2003; 3(4):326-342.
40. Yezierski RP, Liu S, Ruenes GL, Kajander KJ, Brewer KL. Excitotoxic spinal cord injury: behavioral and morphological characteristics of a central pain model. Pain 1998; 75(1):141-155.
41. Jourdan D, Ardid D, Eschalier A. Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain 2002; 95(1-2):165-173.
42. Fox A, Eastwood C, Gentry C, Manning D, Urban L. Critical evaluation of the strepto-zotocin model of painful diabetic neuropathy in the rat. Pain 1999; 81(3):307-316.
43. Apfel SC. Diabetic neuropathy models: are they relevant? Drug Discov Today 2006; 3:397-402.
44. Horowitz SH. Venipuncture-induced neuro-pathic pain: the clinical syndrome, with com-parisons to experimental nerve injury models. Pain 2001; 94(3):225-229.
45. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of dia-betic nephropathy Curr Diab Rep 2004; 4(6):435-440.
46. Mogil JS, Wilson SG, Wan Y. Assessing noci-ception in murine subjects. In: Kruger L, editor. Methods in Pain Research. Boca Raton: CRC Press, 2001: 11-39.
47. Hounsom L, Tomlinson DR. Does neuropathy develop in animal models? Clin Neurosci 1997; 4:380-389.
48. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25(4):612-628.
49. Ruggiero C, Ferrucci L. The endeavor of high maintenance homeostasis: resting metabolic rate and the legacy of longevity. J Gerontol A Biol Sci Med Sci 2006; 61(5):466-471.
50. Greenberg JA, Wei H, Ward K, Boozer CN. Whole-body metabolic rate appears to deter-mine the rate of DNA oxidative damage and glycation involved in aging. Mech Ageing Dev 2000; 115(1-2):107-117.
51. Pittenger GL, Ray M, Burcus NI, McNulty P, Basta B, Vinik AI. Intraepidermal nerve fbers are indicators of small-fber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 2004; 27(8):1974-1979.
52. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy Neurology 1996; 47(4):1042-1048.
53. Lin X, Taguchi A, Park S, Kushner JA, Li F, Li Y et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obe-sity and diabetes. J Clin Invest 2004; 114(7): 908-916.
54. Leonelli E, Bianchi R, Cavaletti G, Caruso D, Crippa D, Garcia-Segura LM et al. Progesterone and its derivatives are neuropro-tective agents in experimental diabetic neu-ropathy: a multimodal analysis. Neuroscience 2007; 144(4):1293-1304.
55. Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C et al. Intraepidermal nerve fber density in rat foot pad: neuro-pathologic- neurophysiologic correlation. J Peripher Nerv Syst 2005; 10(2):202-208.
56. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy Proc Natl Acad Sci USA 2004; 101(3):823-828.
57. Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007; 293(6):E1645-E1655.
58. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a diffcult condi-tion to reverse. Diabetes Obes Metab 2008; 10(1):64-74.
59. Ziegler D, Wiefels K, Dannehl K, Gries FA. Effects of one year of near-normoglycemia on peripheral nerve function in type 1 (insulin-dependent) diabetic patients. Klin Wochenschr 1988; 66(9):388-396.
60. Cardinal JW, Allan DJ, Cameron DP Differential metabolite accumulation may be the cause of strain differences in sensitivity to streptozotocin-induced beta cell death in inbred mice. Endocrinology 1998; 139(6): 2885-2891.
61. Bergen HT, Mizuno T, Taylor J, Mobbs CV. Resistance to diet-induced obesity is associ-ated with increased proopiomelanocortin mRNA and decreased neuropeptide Y mRNA in the hypothalamus. Brain Res 1999; 851(1-2):198-203.
62. Yoon YW, Lee DH, Lee BH, Chung K, Chung JM. Different strains and substrains of rats show different levels of neuropathic pain behaviors. Exp Brain Res 1999; 129(2):167-171.
63. Mogil JS. The genetic mediation of individ-ual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA 1999; 96(14):7744-7751.
64. Simone DA, Marchettini P, Caputi G, Ochoa JL. Identifcation of muscle afferents sub-serving sensation of deep pain in humans. J Neurophysiol 1994; 72(2):883-889.
65. Laursen RJ, Graven-Nielsen T, Jensen TS, Arendt-Nielsen L. The effect of differential and complete nerve block on experimental muscle pain in humans. Muscle Nerve 1999; 22(11):1564-1570.
66. Graven-Nielsen T, Mense S, Arendt-Nielsen L. Painful and non-painful pressure sensa-tions from human skeletal muscle. Exp Brain Res 2004; 159(3):273-283.
67. Randall LO, Selitto JJ. A method for mea-surement of analgesic activity on infamed tissue. Arch Int Pharmacodyn Ther 1957; 111(4):409-419.
68. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J. Hyperalgesia in sponta-neous and experimental animal models of diabetic neuropathy Diabetologia 1987; 30:653-658.
69. Zhuang H-X, Wuarin L, Fei Z-J, Ishii DN. Insulin-like growth factor (IGF) gene expres-sion is reduced in neural tissues and liver from rats with non-insulin-dependent diabe-tes mellitus, and IGF treatment ameliorates diabetic neuropathy J Pharmacol Exp Ther 1997; 283(1):366-374.
70. Tishler M, Smorodin T, Vazina-Amit M, Ramot Y, Koffer M, Fishel B. Fibromyalgia in diabetes mellitus. Rheumatol Int 2003; 23(4):171-173.
71. Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol 2007; 13:175-191.
72. Torebjörk HE, Lundberg LER, LaMotte RH. Central changes in processing of mecha-noreceptive input in capsaicin-induced sec-ondary hyperalgesia in humans. J Physiol 1992; 448:765-780.
73. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing main-tained dynamically by peripheral input. Pain 1992; 51:175-194.
74. Cervero F, Laird JM. Mechanisms of touch-evoked pain (allodynia): a new model. Pain 1996; 68(1):13-23.
75. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozoto-cin-induced diabetes. J Peripher Nerv Syst 2004; 9(2):62-69.
76. Chen SR, Pan HL. Hypersensitivity of spi-nothalamic tract neurons associated with dia-betic neuropathic pain in rats. J Neurophysiol 2002; 87(6):2726-2733.
77. Ilnytska O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy Diabetes 2006; 55(6):1686-1694.
78. Hoybergs YM, Meert TF. The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy Neurosci Lett 2007; 417(2):149-154.
79. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalge-sia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lido-caine. Pain 1996; 68:293-299.
80. Khan GM, Chen SR, Pan HL. Role of pri-mary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 2002; 114:291-299.
81. Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neu-rotrophic factor. Diabetologia 2004; 47(4): 718-724.
82. Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by gabapentin of K+-evoked release of [3H)-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 2004; 141(4): 574-579.
83. Li F, Obrosova IG, Abatan O, Tian D, Larkin D, Stuenkel EL et al. Taurine replacement attenuates hyperalgesia and abnormal cal-cium signaling in sensory neurons of STZ-D rats. Am J Physiol Endocrinol Metab 2005; 288(1):E29-E36.
84. Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced infammatory and streptozotocin-induced diabetic neuropathy J Pharmacol Sci 2008; 107(2):213-220.
85. Rashid MH, Inoue M, Bakoshi S, Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons con-tributes to the antihyperalgesic effect of cap-saicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther 2003; 306(2): 709-717.
86. Dias JP, Ismael MA, Pilon M, de Champlain J, Ferrari B, Carayon P et al. The kinin B1 receptor antagonist SSR240612 reverses tac-tile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol 2007; 152(2):280-287.
87. Christianson JA, Ryals JM, Johnson MS, Dobrowsky RT, Wright DE. Neurotrophic modulation of myelinated cutaneous inner-vation and mechanical sensory loss in diabetic mice. Neuroscience 2007; 145(1):303-313.
88. Kontinen VK, Meert TF. Predictive validity of neuropathic pain models in pharmacologi-cal studies with a behavioral outcome in the rat: a systematic review. In: Dostrovsky JO, Carr DL, Koltzenburg M, editors. Proceedings of the Tenth World Congress on Pain. Seattle: IASP Press, 2004: 489-498.
89. Ahlgren SC, White DM, Levine JD. Increased responsiveness of sensory neurons in the saphenous nerve of the streptozotocin-diabetic rat. J Neurophysiol 1992; 68(6):2077-2085.
90. Bove G. Mechanical sensory threshold testing using nylon monoflaments: the pain feld's "tin standard". Pain 2006; 124(1-2):13-17.
91. Kramer HH, Rolke R, Bickel A, Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. Diabetes Care 2004; 27(10):2386-2391.
92. Courteix C, Eschalier A, lavarenne J. Streptozocin-induced diabetic rats: behav-ioural evidence for a model of chronic pain. Pain 1993; 53(1):81-88.
93. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase Cbeta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002; 103:311-321.
94. Forman LJ, Estilow S, Lewis M, Vasilenko P. Streptozocin diabetes alters immunoreactive ß-endorphin levels and pain perception after 8 wk in female rats. Diabetes 1986; 35: 1309-1313.
95. Gabra BH, Benrezzak O, Pheng LH, Duta D, Daull P, Sirois P et al. Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worchester rats: effcacy of a selective bradyki-nin B1 receptor antagonist. J Neuropathol Exp Neurol 2005; 64(9):782-789.
96. Lee JH, McCarty R. Pain threshold in dia-betic rats: effects of good versus poor dia-betic control. Pain 1992; 50(2):231-236.
97. Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER et al. Cell-specifc alterations of T-type cal-cium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 2007; 27(12):3305-3316.
98. Malcangio M, Tomlinson DR. A pharmaco-logic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 1998; 76: 151-157.
99. Sugimoto K, Rashid IB, Shoji M, Suda T, Yasujima M. Early changes in insulin recep-tor signaling and pain sensation in streptozo-tocin-induced diabetic neuropathy in rats. J Pain 2008; 9(3):237-245.
100. Chu PC, Lin MT, Shian LR, Leu SY. Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 1986; 35(4):481-485.
101. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL. Tolrestat treatment prevents mod-ifcation of the formalin test model of pro-longed pain in hyperglycemic rats. Pain 1994; 58:413-420.
102. Rutledge LP, Ngong JM, Kuperberg JM, Samaan SS, Soliman KF, Kolta MG. Dopaminergic system modulation of nocice-ptive response in long-term diabetic rats. Pharmacol Biochem Behav 2002; 74(1):1-9.
103. Apfel SC, Arezzo JC, Brownlee M, Fedoroff H, Kessler JA. Nerve growth factor adminis-tration protects against experimental sensory neuropathy. Brain Res 1994; 634:7-12.
104. Kamiya H, Zhang W, Sima AA. Degeneration of the golgi and neuronal loss in dorsal root ganglia in diabetic biobreeding/Worcester rats. Diabetologia 2006; 49(11): 2763-2774.
105. Kamiya H, Murakawa Y, Zhang W, Sima AA. Unmyelinated fber sensory neuropathy dif-fers in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005; 21(5):448-458.
106. Roane DS, Porter JR. Nociception and opi-oid-induced analgesia in lean (Fa/-) and obese (fa/fa) Zucker rats. Physiol Behav 1986; 38(2):215-218.
107. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su OS, Lentz SI et al. Mouse models of diabetic neuropathy. Neurobiol Dis 2007; 28(3):276-285.
108. Pabbidi RM, Yu SQ, Peng S, Khardori R, Pauza ME, Premkumar LS. Infuence of TRPV1 on diabetes-induced alterations in thermal pain sensitivity. Mol Pain 2008; 4:9.
109. Davar G, Waikar S, Eisenberg E, Hattori M, Thalhammer JG. Behavioral evidence of ther-mal hyperalgesia in non-obese diabetic mice with and without insulin-dependent diabetes. Neurosci Lett 1995; 190(3):171-174.
110. Ohsawa M, Kamei J. Role of intracellular cal-cium in thermal allodynia and hyperalgesia in diabetic mice. Brain Res 1999; 833(2): 278-281. (Pubitemid 29333803)
111. Osei K, Rhinesmith S, Gaillard T, Schuster D. Impaired insulin sensitivity, insulin secre-tion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic African Americans: implications for primary diabetes prevention. Diabetes Care 2004; 27(6): 1439-1446.
112. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood fow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004; 287(3):E497-E505.
113. Yeomans DC, Pirec V, Proudft HK. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain 1996; 68(1):133-140.
114. Cheppudira BP. Characterization of hind paw licking and lifting to noxious radiant heat in the rat with and without chronic infammation. J Neurosci Methods 2006; 155(1):122-125.
115. Ochoa JL, Yarnitsky D. Mechanical hyperal-gesias in neuropathic pain patients: dynamic and static subtypes. Ann Neurol 1993; 33(5):465-472.
116. Kastenbauer T, Irsigler P, Sauseng S, Grimm A, Prager R The prevalence of symptoms of sensorimotor and autonomic neuropathy in type 1 and type 2 diabetic subjects. J Diabetes Complications 2004; 18(1):27-31.
117. Dutta A, Naorem S, Singh TP, Wangjam K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetics. Int J Diab Dev Countries 2005; 25:30-33.
118. Colin IM, Bouhassira D, Weiss K, Matthys K, Mathieu C, Van Acker K. Prevalence of polyneuropathy and neuropathic pain in type 1 and 2 diabetic patients and association with metabolic syndrome parameters. Diabetes 2007; 56(1 Suppl):A209.
119. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993; 16(11):1446-1452.
120. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38(11):1456-1461.
121. Comi G, Canal N, Lozza L, Beccaria L, Meschi F, Vanini R et al. Peripheral nerve abnormali-ties in newly-diagnosed diabetic children. Acta Diabetol Lat 1986; 23(1):69-75.
122. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(2):89-94.
123. Cheng WY, Jiang YD, Chuang LM, Huang CN, Heng LT, Wu HP et al. Quantitative sensory testing and risk factors of diabetic sensory neuropathy J Neurol 1999; 246(5):394-398.
124. Boru UT, Alp R, Sargin H, Kocer A, Sargin M, Luleci A et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attend-ing a diabetes center in Turkey. Endocr J 2004; 51(6):563-567.
125. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C et al. Vascular risk factors and diabetic neuropathy N Engl J Med 2005; 352(4):341-350.
126. Sibal L, Law HN, Gebbie J, Home P. Cardiovascular risk factors predicting the development of distal symmetrical polyneu-ropathy in people with type 1 diabetes: a 9-year follow-up study. Ann N Y Acad Sci 2006; 1084:304-318.
127. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008; 31(1 Suppl):S12-S54.
128. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L et al. Chronic com-plications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22(8):1347-1353.
129. Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F. Diabetic neuropathy in patients with "latent autoimmune diabe-tes of the adults" (LADA) compared with patients with type 1 and type 2 diabetes. J Neurol 2003; 250(6):682-687.
130. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M et al. Prevalence of microalbuminuria, arterial hypertension, retin-opathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296(6616):156-160.
131. Chao CC, Hsieh SC, Yang WS, Lin YH, Lin WM, Tai TY et al. Glycemic control is related to the severity of impaired thermal sensations in type 2 diabetes. Diabetes Metab Res Rev 2007; 23(8):612-620.
132. Claus D, Mustafa C, Vogel W, Herz M, Neundorfer B. Assessment of diabetic neuropathy: defnition of norm and discrimi-nation of abnormal nerve function. Muscle Nerve 1993; 16(7):757-768.
133. Sima AAF, Shafrir E editors. Animal Models of Diabetes. Amsterdam: Harwood Academic Publishers, 2001: 109-128.
134. Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev 1987; 3(3):725-750.
135. Pederson RA, Curtis SB, Chisholm CB, Gaba NR, Campos RV, Brown JC. Insulin secre-tion and islet endocrine cell content at onset and during the early stages of diabetes in the BB rat: effect of the level of glycemic control. Can J Physiol Pharmacol 1991; 69(8): 1230-1236.
136. Kanazawa M, Ikeda J, Sato J, Natoya Y, Ito H, Komeda K et al. Alteration of insulin and glucagon secretion from the perfused BB rat pancreas before and after the onset of dia-betes. Diabetes Res Clin Pract 1988; 5(3): 201-204.
137. Reddy S, Bibby NJ, Fisher SL, Elliott RB. Longitudinal study of frst phase insulin release in the BB rat. Diabetologia 1986; 29(11):802-807.
138. Svenningsen A, Dyrberg T, Markholst H, Binder C, Lernmark A. Insulin release and pancreatic insulin is reduced in young predia-betic BB rats. Acta Endocrinol (Copenh) 1986; 112(3):367-371.
139. Gabra BH, Sirois P. Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor. Eur J Pharmacol 2005; 514(1):61-67.
140. Hallfrisch J, Cohen L, Reiser S. Effects of feeding rats sucrose in a high fat diet. J Nutr 1981; 111(3):531-536.
141. Kim JY, Nolte LA, Hansen PA, Han DH, Kawanaka K, Holloszy JO. Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet. Am J Physiol 1999; 276(3 Pt 2):R665-R672.
142. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity Hypertension 2000; 35(4):1009-1015.
143. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacologi-cal screening. Pharmacol Res 2005; 52(4):313-320.
144. Erdei N, Toth A, Pasztor ET, Papp Z, Edes I, Koller A et al. High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. Am J Physiol Heart Circ Physiol 2006; 291(5):H2107-H2115.
145. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J et al. Defning high-fat-diet rat models: meta-bolic and molecular effects of different fat types. J Mol Endocrinol 2006; 36(3):485-501.
146. Budohoski L, Challiss RA, Cooney GJ, McManus B, Newsholme EA. Reversal of dietary-induced insulin resistance in muscle of the rat by adenosine deaminase and an adenosine-receptor antagonist. Biochem J 1984; 224(1):327-330.
147. El Midaoui A, Ongali B, Petcu M, Rodi D, de Champlain J, Neugebauer W et al. Increases of spinal kinin receptor binding sites in two rat models of insulin resistance. Peptides 2005; 26(8):1323-1330.
148. Kava R, Greenwood MRC, Johnson PR. Zucker (fa/fa) rat. Ilar News 1990; 32:4-8.
149. Griffen SC, Wang J, German MS. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 2001; 50(1):63-68.
150. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent dia-betes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000; 148(2):231-241.
151. Durham HA, Truett GE. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 2006; 290(3):R652-R658.
152. Tirabassi RS, Flanagan JF, Wu T, Kislauskis EH, Birckbichler PJ, Guberski DL. The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus. ILAR J 2004; 45(3):292-302.
153. Poirier B, Lannaud-Bournoville M, Conti M, Bazin R, Michel O, Bariety J et al. Oxidative stress occurs in absence of hyperglycaemia and infammation in the onset of kidney lesions in normotensive obese rats. Nephrol Dial Transplant 2000; 15(4):467-476.
154. Oltman CL, Coppey LJ, Gellett JS, Davidson EP, Lund DD, Yorek MA. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab 2005; 289(1):E113-E122.
155. Weis J, Dimpfel W, Schroder JM. Nerve con-duction changes and fne structural alterations of extra-and intrafusal muscle and nerve fbers in streptozotocin diabetic rats. Muscle Nerve 1995; 18(2):175-184.
156. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999; 6:347-363.
157. Sima AAF. Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study. Acta Neuropathol (Berl) 1980; 51:223-227.
158. Sima AAF, Ristic H, Merry A, Kamijo M, Lattimer SA, Stevens MJ et al. Primary pre-ventive and secondary interventionary effects of acetyl-l-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996; 97(8):1900-1907.
159. 1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur J Pharmacol 1993; 241:267-270.
160. Courteix C, Bardin M, Chantelauze C, lava-renne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994; 57(2):153-160.
161. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase acti-vation in neurons and microglia via N-methyl-d-aspartate- dependent mechanisms. Mol Pharmacol 2006; 70(4):1246-1254.
162. Ahlgren SC, Levine JD. Mechanical hyperal-gesia in streptozotocin- diabetic rats is not sympathetically maintained. Brain Res 1993; 616:171-175.
163. Courteix C, Bardin M, Massol J, Fialip J, lavarenne J, Eschalier A. Daily insulin treat-ment relieves long-term hyperalgesia in streptozocin diabetic rats. Neur oreport 1996; 7(12):1922-1924.
164. Zhuang HX, Snyder CK, Pu SF, Ishii DN. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996; 140(2):198-205.
165. Sasaki T, Yasuda H, Maeda K, Kikkawa R Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 1998; 9:243-247.
166. Kim H, Sasaki T, Maeda K, Koya D, Kashiwagi A, Yasuda H. Protein kinase Cbeta selective inhibitor LY333531 attenuates dia-betic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes 2003; 52:2102-2109.
167. Chen SR, Pan HL. Antinociceptive effect of morphine, but not mu opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003; 99(6):1409-1414.